CLL

Treatment with NX-2127 provides clinically meaningful responses in heavily pretreated chronic lymphocytic leukemia (CLL) patients regardless of Bruton’s tyrosine kinase (BTK) mutational status BTK mutations conferring resistance to both…

SAN DIEGO, Aug. 25, 2022 (GLOBE NEWSWIRE) -- Bionano Genomics, Inc. (Nasdaq: BNGO) today announced the publication of the first study to use optical genome mapping (OGM) to analyze the impact of chromothripsis (cth) and TP53…

BMF-219 is the first investigational menin inhibitor in clinical development to show potential as a therapeutic agent for CLLBMF-219, a covalent menin inhibitor, demonstrated potency across ex vivo CLL tumor models with varying cytogenetic…

Company voluntarily withdraws UKONIQ® from sale for approved indications of relapsed/refractory MZL and FL Company to host conference call, Monday, April 18, 2022 at 8:30 AM ET NEW YORK, April 15, 2022 (GLOBE NEWSWIRE) -- TG…

Newly diagnosed patients with chronic lymphocytic leukemia (CLL) have a plethora of treatment options, and making the right choice requires careful consideration of the individual…

ATLANTA -- A chemotherapy-free regimen significantly improved progression-free survival (PFS) versus chemoimmunotherapy as initial treatment for chronic lymphocytic leukemia (CLL),…

Chronic lymphocytic leukemia (CLL) is a disease of older age, diagnosed typically at age 70, but life expectancy has increased substantially, according to one expert. "About 30% to…

ATLANTA -- Roughly nine of 10 so-called fit patients with chronic lymphocytic leukemia (CLL) achieved undetectable minimal residual disease (MRD) status after treatment with one of…

SEATTLE, Sept. 30, 2021 (GLOBE NEWSWIRE) -- Adaptive Biotechnologies Corporation (Nasdaq: ADPT), a commercial stage biotechnology company that aims to translate the genetics of the adaptive immune system into clinical products to…

Use of the Bruton tyrosine kinase (BTK) inhibitor ibrutinib (Imbruvica) was linked with cardiovascular risks in patients with chronic lymphocytic…